NCT01323062View on ClinicalTrials.gov

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

May 14, 2014

Study Completion Date

October 1, 2018

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Bavituximab

Administered 3 mg/kg weekly

Trial Locations (2)

15232

University of Pittsburgh Medical Center, Pittsburgh

27599

Lineberger Comprehensive Cancer Center, UNC, Chapel Hill

Sponsors

Collaborators (1)

Peregrine Pharmaceuticals

All Listed Sponsors

collaborator

Peregrine Pharmaceuticals

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER